Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Isoniazid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Isoniazid. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-002000-31 Sponsor Protocol Number: FSJD-ISON-2016 Start Date*: 2016-09-21
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: Open clinical trial phase IIa to study the isoniazid suspension absoption of 10mg/ml for the tuberculosis infection treatment in patients under the age of 6
    Medical condition: tuberculosis infection in patients under the age of 6
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003387-22 Sponsor Protocol Number: Start Date*: 2007-10-07
    Sponsor Name:Pharma 2100 ApS
    Full Title: Et velkendt lægemiddels helende effekt på iskæmiske sår: et randomiseret dobbelt-blindt placebokontrolleret pilotforsøg
    Medical condition: Out-patients with ischemic (arterial) leg ulcers (systolic toe pressure: < 40 mm Hg).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005142-12 Sponsor Protocol Number: TMC207-C203 Start Date*: 2005-06-25
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of...
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003312-29 Sponsor Protocol Number: UITB Estudio 28 Start Date*: 2006-05-17
    Sponsor Name:TB Investigation Unit of Barcelona
    Full Title: Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28
    Medical condition: To compare two treatments for pulmonary tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000750-21 Sponsor Protocol Number: 12/0426 Start Date*: 2013-12-18
    Sponsor Name:University College London
    Full Title: The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI)
    Medical condition: Latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000224-41 Sponsor Protocol Number: IDANAT2 Start Date*: 2008-08-26
    Sponsor Name:University of Cologne
    Full Title: A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransfe...
    Medical condition: pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002094-58 Sponsor Protocol Number: UITB-TBTC-Estudio33 Start Date*: 2012-10-26
    Sponsor Name:Unidad de Investigación en Tuberculosis de Barcelona (UITB)
    Full Title: An evaluation of adherence to LTBI treatment with 12 doses of once weekly rifapentine and isoniazid given as self-administered versus directly-observed therapy: iAdhere
    Medical condition: Adherence study in subjects with Latent Tuberculosis Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002063-95 Sponsor Protocol Number: ASST-ITL-FARMA-INFE-2019 Start Date*: 2020-05-29
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tu...
    Medical condition: latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000090-32 Sponsor Protocol Number: BBR-012CS01 Start Date*: 2011-05-12
    Sponsor Name:Bridge BioResearch Rights (Jersey) Ltd
    Full Title: A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diab...
    Medical condition: Complicated skin ulceration on the foot in patients with diabetes.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10067106 Multiple skin ulcers LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003567-20 Sponsor Protocol Number: A101A Start Date*: 2017-04-21
    Sponsor Name:Dept of Infectious Diseases, Aarhus University Hospital
    Full Title: A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI...
    Medical condition: Latent tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001173-69 Sponsor Protocol Number: 126496 Start Date*: 2020-10-22
    Sponsor Name:Pernille Ravn
    Full Title: Impact of LTBI treatment on glucose tolerance and chronic inflammation
    Medical condition: latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000850-36 Sponsor Protocol Number: 201600136 Start Date*: 2017-05-01
    Sponsor Name:Archivel Farma S.L.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos...
    Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004473-25 Sponsor Protocol Number: 242-12-232 Start Date*: 2018-09-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Pat...
    Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDRTB) who are receiving an optimized background regimen (OBR) of Antituberculosis Drugs
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004620-38 Sponsor Protocol Number: 242-12-233 Start Date*: 2019-01-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therap...
    Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDR-TB) who are receiving an optimized background regimen (OBR) of antituberculosis drugs
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001438-20 Sponsor Protocol Number: ASSTBS-FARM-INF_ITL-2021 Start Date*: 2021-05-10
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Randomized controlled trial on daily Rifampicin for Four Months Compared with daily Rifampicin/Isoniazid for Three Months for the Treatment of Tuberculosis Infection among migrants: Completion Rate...
    Medical condition: Tuberculosis Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000982-51 Sponsor Protocol Number: P05336 Start Date*: 2009-07-01
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Medical condition: Moderate-to-severe active axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058338 Spondylarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) DE (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003633-24 Sponsor Protocol Number: UITB-Study-29 Start Date*: 2009-01-08
    Sponsor Name:TB Investigation Unit of Barcelona
    Full Title: Evaluation of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis Evaluación de una Pauta con Rifapentina para la Fase Intensiva del tratamiento de la Tub...
    Medical condition: To compare two treatments for Pulmonary Tuberculosis Comparar dos tratamientos para la tuberculosis pulmonar
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022271-59 Sponsor Protocol Number: 242-09-213 Start Date*: 2011-07-19
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dos...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10037443 Pulmonary tuberculosis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004578-27 Sponsor Protocol Number: A3921094 Start Date*: 2012-04-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) HU (Completed) EE (Completed) LV (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) SK (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:19:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA